Anbenitamab

DB18411InvestigationalProtein Based Therapies

Anbenitamab: Overview.

Mechanism
Curator reviewed
Also known as
ANTI-HER2 BSAB KN026 · FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4 · IMMUNOGLOBULIN G1 (369-SERINE,371-ALANINE,408-LYSINE,410-VALINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2 DOMAIN IV)(HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB 4D5 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB 4D5 .KAPPA.-CHAIN
Code names
KN-026

Resolves to

Compound
UNIIRHS90QRF9ECAS2367012-88-0
Targets
P04626ERBB2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
17Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Anbenitamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In